Altimmune (ALT) Interest & Investment Income (2010 - 2026)

Altimmune (ALT) has 15 years of Interest & Investment Income data on file, last reported at $2.9 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 87.77% year-over-year to $2.9 million in Q1 2026; TTM through Mar 2026 was $8.9 million, a 23.47% increase from a year earlier, with the FY2025 full-year figure at $7.5 million, down 6.6% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $2.9 million, up from $2.4 million in the prior quarter.
• Over the last five years, Interest & Investment Income for ALT reached as high as $2.9 million in Q1 2026 and fell as low as $21000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.7 million across 5 years, with a median of $1.8 million in 2023.
• On a YoY basis, Interest & Investment Income climbed as much as 8000.0% in 2022 and fell as far as 50.0% in 2022.
• Year by year, Interest & Investment Income stood at $1.5 million in 2022, then jumped by 33.79% to $2.0 million in 2023, then dropped by 20.11% to $1.6 million in 2024, then soared by 55.39% to $2.4 million in 2025, then gained by 18.99% to $2.9 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $2.9 million in Q1 2026, $2.4 million in Q4 2025, and $2.4 million in Q3 2025.